Salta ai contenuti. | Salta alla navigazione

Strumenti personali

AirPROM

Airway Disease PRedicting Outcomes through Patient Specific Computational Modelling

 

Website

Project details:

Start date 01/03/2011 - end date 28/02/2016
Total cost: 15.528.124 €
EU contribution: 11.713.194 €
EU contribution to UniFe: 54.998 €

 

Abstract:

The airways diseases asthma and chronic obstructive pulmonary disease affect over 400 million people world-wide and cause considerable morbidity and mortality. Airways disease costs the European Union in excess of €56 billion per annum. Current therapies are inadequate and we do not have sufficient tools to predict disease progression or response to current or future therapies. Our consortium, Airway Disease PRedicting Outcomes through Patient Specific Computational Modelling (AirPROM), brings together the exisiting clinical consortia (EvA FP7, U-BIOPRED IMI and BTS Severe Asthma), and expertise in physiology, radiology, image analysis, bioengineering, data harmonization, data security and ethics, computational modeling and systems biology. We shall develop an integrated multi-scale model building upon existing models. This airway model will be comprised of an integrated 'micro-scale' and 'macro-scale' airway model informed and validated by 'omic data and ex vivo models at the genome-transcriptome-cell-tissue scale and by CT and functional MRI imaging coupled to detailed physiology at the tissue-organ scale utilising Europe's largest airway disease cohort. Validation will be undertaken cross-sectionally, following interventions and after longitudinal follow-up to incorporate both spatial and temporal dimensions. AirPROM has a comprehensive data management platform and a well-developed ethico-legal framework. Critically, AirPROM has an extensive exploitation plan, involving at its inception and throughout its evolution those that will 'develop' and 'use' the technologies emerging from this project. AirPROM therefore will bridge the critical gaps in our clinical management of airways disease, by providing validated models to predict disease progression and response to treatment and the platform to translate these patient-specific tools, so as to pave the way to improved, personalised management of airways disease.

 

Participants:

  • UNIVERSITY OF LEICESTER (United Kingdom)
  • HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH (DE)
  • Academisch Medisch Centrum bij de Universiteit van Amsterdam (Netherlands)
  • IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE (United Kingdom)
  • QUEEN'S UNIVERSITY BELFAST (United Kingdom)
  • THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (United Kingdom)
  • THE UNIVERSITY OF NOTTINGHAM (United Kingdom)
  • THE UNIVERSITY OF SHEFFIELD (United Kingdom)
  • Institut Telecom (France)
  • THE UNIVERSITY OF WARWICK (United Kingdom)
  • FUNDACIO PRIVADA PARC CIENTIFIC DE BARCELONA (Spain)
  • MATERIALISE NV (Belgium)
  • ANSYS UK LIMITED (United Kingdom)
  • INSTYTUT CHEMII BIOORGANICZNEJ (Poland)
  • FluidDA nv (Belgium)
  • BIOMAX INFORMATICS AG (Germany)
  • EUROPEAN RESPIRATORY SOCIETY (Switzerland)
  • BIOSCI CONSULTING (Belgium)
  • UNIVERSITY OF SOUTHAMPTON (United Kingdom)
  • UNIVERSITA DEGLI STUDI DI CATANIA (Italy)
  • SEMMELWEIS EGYETEM (Hungary)
  • THE UNIVERSITY OF MANCHESTER (United Kingdom)
  • UNIVERSITE DE LA MEDITERRANEE D'AIX-MARSEILLE II (France)
  • UMEA UNIVERSITET (Sweden)
  • KAROLINSKA INSTITUTET (Sweden)
  • OBJET GEOMETRIES GMBH (Germany)
  • EUROPEAN FEDERATION OF ASTHMA &ALLERGY ASSOCIATIONS IDEELL FORENING (Belgium)
  • INSTYTUT GRUZLICY I CHOROB PLUC (Poland)
  • VASTRA GOTALANDS LANS LANDSTING (Sweden)
  • ORSZAGOS KORANYI TBE ES PULMONOLOGIAI INTEZET (Hungary)
  • COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (France)
  • UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NATIONAL HEALTH SERVICE TRUST (United Kingdom)
  • European Lung Foundation (United Kingdom)